Sujana Biotech, a biotechnology company developing novel therapeutics to prevent inflammatory and vascular disorders, today announced new funding from the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke at the National Institutes for Health. The funding from this $219,029 grant will support the development of a monoclonal antibody for the treatment of multiple sclerosis (MS).
Nature Communications has published the research of Daniel I. Simon, M.D.; Edward Plow, Ph.D.; and Yunmei Wang, Ph.D. - Founders of Sujana Biotech - which describes a novel target for thrombotic disorders that does not effect hemostasis (bleeding time).
Sujana Biotech has been awarded a $805,182 grant to support the development of a novel therapeutic for the treatment of a range of vascular and inflammatory diseases.
Sujana Biotech announces funding from the National Heart Lung and Blood Institute to support the development of a novel anti-thrombotic therapeutic. BioAtla, a long time collaborator, was awarded a Phase I SBIR grant of $220,268 to support the development of Sujana's platform technology. The technology has potential applications over a range of inflammatory and vascular disorders.
In April, Dr. Simon will be presented with the 2016 Distinguished Scientist Award – Basic Domain by the American College of Cardiology at the ACC’s 65th Annual Scientific Session. The award is in honor of his lasting contributions and achievements in the cardiovascular profession, and his dedication to both patient care and clinical research. Dr. Simon serves as the President of University Hospitals Cleveland Medical Center and the UH Harrington Heart & Vascular Institute. Sujana Biotech (www.sujanabio.com) is based on his discoveries
Sujana Biotech is a company developing novel therapeutics for a range of inflammatory and vascular disorders. The company is being launched by BioMotiv in partnership with scientific founder and Harrington Scholar Daniel Simon, MD (University Hospitals Harrington Heart & Vascular Institute)and his colleagues Edward Plow, PhD (Cleveland Clinic) and Yunmei Wang, PhD (Case Western Reserve University). The founders have identified a unique binding site on the leukocyte integrin Mac-1 that is responsible for the pathologic recruitment and activation of leukocytes at sites of vascular injury. The technology is licensed from Case Western Reserve University.